Compare Extra Space Storage, Inc. (EXR) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Extra Space Storage, Inc. vs Vertex Pharmaceuticals Incorporated — how do they compare? Extra Space Storage, Inc. trades at $133.26 (market cap $28.12B), while Vertex Pharmaceuticals Incorporated trades at $503.25 (market cap $127.55B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 4.5× Extra Space Storage, Inc.'s market cap, and Extra Space Storage, Inc. pays a 4.87% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals — on Pluang, investors hold Extra Space Storage, Inc. for 108 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| EXR | VRTX | |
|---|---|---|
Market Cap | $28.12B | $127.55B |
Volume | 2,595,579 | 1,487,944 |
Sector | Real Estate | Health |
52-Week High | $152.85 | $557.96 |
52-Week Low | $126.67 | $407.37 |
Typical Hold Time | 108 Days | 120 Days |
Enterprise Value | $41.84B | $121.68B |
Dividend Yield | 4.87% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Extra Space Storage (EXR) trades at $131.70, down 1.64% with a bearish technical signal. The company maintains strong fundamentals with consistent earnings beats, 27.79% net margin, and $974M net income. Revenue growth has been steady from $1.9B in 2022 to $3.4B in 2025. Analyst consensus is split with 14 Buy and 14 Hold ratings, targeting $158.33 average price. Recent leadership transition to Noah Springer as CEO effective January 2027 adds strategic focus.
EXR presents a balanced risk-reward profile with solid operational performance offset by technical weakness. The REIT's scale, 94.2% occupancy, and dividend yield support long-term value, though current price action suggests near-term pressure. Debt levels at 46.63% debt-to-asset ratio require monitoring amid rising interest rates. Upside potential exists if Q3 2026 earnings beat expectations on October 27.
Vertex Pharmaceuticals (VRTX) trades at $505.64, up 0.63% on the day, with a bearish technical signal despite a neutral oscillator reading. The company reported strong 2025 revenue of $12.00B and net income of $3.95B, with a net margin of 35%. Recent positive Phase 2b data for its kidney disease drug inaxaplin highlights pipeline expansion beyond cystic fibrosis dominance. Analyst consensus is strongly bullish with an 83.9% buy rating and a $573.50 price target, implying 13.4% upside.
The outlook for VRTX is positive, driven by its profitable core business and promising pipeline, but faces risks from clinical trial outcomes and competitive pressures. The stock's current valuation at a P/E of 29.45 is reasonable given its growth prospects, though investors should monitor execution on new drug approvals and market adoption.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Extra Space Storage, Inc.
Extra Space Storage is a fully integrated real estate investment trust that owns, operates, and manages almost 2,100 self-storage properties in 41 states, with over 160 million net rentable square feet of storage space. Of these properties, approximately one half is wholly owned, while some facilities are owned through joint ventures and others are owned by third parties and managed by Extra Space Storage in exchange for a management fee.
Read more on EXR →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
